ClinConnect ClinConnect Logo
Search / Trial NCT07131917

Bedside Monitoring of Microenvironmental Changes in Infected Pancreatic Collections

Launched by MARTIN HARAZIM · Aug 13, 2025

Trial Information

Current as of November 06, 2025

Not yet recruiting

Keywords

Pancreatitis

ClinConnect Summary

This clinical study is exploring a new way to closely watch changes inside infected pockets of dead tissue in the pancreas, a serious problem that can happen after pancreatitis (inflammation of the pancreas). These infected areas, called walled-off pancreatic necrosis (WOPN), often need to be drained or treated with surgery. The study will use a tiny, sterile sensor placed directly into the infected area during a routine drainage procedure to measure things like acidity and other local chemical changes. The goal is to see if these measurements can help doctors better understand how severe the infection is and how well treatments are working.

Adults diagnosed with infected WOPN who are already scheduled for drainage may be eligible to join, as long as they can safely have the sensor placed and agree to participate. Taking part means the sensor will be used briefly during standard care, but no new treatments will be given. Patients will continue to receive all usual treatments such as antibiotics and imaging tests. Participation is completely voluntary, and only those who give informed consent will be enrolled. This study aims to improve how infections in the pancreas are monitored, which could help guide treatment decisions in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years
  • Diagnosis of walled-off pancreatic necrosis (WOPN) confirmed by imaging (CT, MRI, or EUS)
  • Clinical suspicion or confirmation of infection in WOPN (e.g., fever, elevated inflammatory markers, positive culture)
  • Planned percutaneous drainage as part of standard care
  • Ability to provide informed consent (or surrogate consent where applicable)
  • Exclusion Criteria:
  • Coagulopathy not correctable prior to intervention (e.g., INR \> 2.0 or platelets \< 50×10⁹/L)
  • Known allergy or hypersensitivity to materials used in the monitoring probe
  • technical limitations precluding safe probe insertion

About Martin Harazim

Martin Harazim is a dedicated clinical trial sponsor committed to advancing medical research through the support and oversight of rigorous, ethical clinical studies. With a focus on innovation and patient safety, Martin Harazim facilitates the development of new therapies and contributes to the enhancement of healthcare outcomes.

Locations

Brno, Czechia

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported